Mixed Effects Models in Drug Stability
Tuesday 3 June, 10:20--12:10
- Organizer: Jim COLAIANNE
- Merck Sharp \& Dohme
- Moderator: Jim COLAIANNE
- Merck Sharp \& Dohme
- John MURPHY
- Eli Lilly, Indianapolis, IN, USA
Methods for determining shelf life, expiry limit, and release limits are
developed and compared. The FDA/ICH method is compared to random slopes
methods based on ANOVA Estimators and to Maximum Likelihood Estimators
from SAS Proc Mixed. The performance of the methods is compared on the
basis of the bias and precision of the estimates generated.
[John Murphy, Eli Lilly, Drop Code 2233,
Lilly Corporate Ctr, Indianapolis, IN 46285-0002]
- Arthur R SILVERBERG
- Trilogy Consulting Corporation, Princeton, NJ, USA
For pharmaceutical products, a stability study is normally conducted
to calculate a shelf life (expiratory dating period). A comparison of
several methods for computing the expiration dating period (shelf
life) is explored using real datasets. All methods are based upon a
regression procedure. The method for the traditional NDA three batch
sample is to consider batches as fixed and take the batch with the
shortest expiration dating period. When marketing batches become
available there may be many more than three batches and this fixed
effects methodology may not give reasonable answers. Fixed effects
methods include calculating using fixed effects regression models with
and without common error, and common slope. Random coefficients
models were also fit with slopes and intercepts independent and with
an unstructured covariance matrix. Prediction limits, confidence
limits and tolerance limits were calculated with these random effects
models and compared to the fixed effects models.
[Arthur R. Silverberg, Trilogy Consulting Corporation, USA.]
Back to JRC program
Back to JRC Home Page